Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Review published in Current opinion in rheumatology (2023)
Abstract
PURPOSE OF REVIEW: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types. RECENT FINDINGS: APS represents a disease spectrum. Although thrombosis and pregnancy morbidities are traditional hallmarks of APS, a variety of extra-criteria clinical phenotypes can often be seen, which makes clinical management more challenging. Primary APS thrombosis prophylaxis should take a risk-stratified approach. Although vitamin K antagonists (VKAs) or heparin/low molecular weight heparin (LMWH) remain the preferred treatment for secondary APS thrombosis prophylaxis, some international society guidelines support the use of direct oral anticoagulants (DOACs) in certain circumstances. Careful monitoring and individualized obstetric care with the use of aspirin and heparin/LMWH will improve pregnancy outcomes among pregnant individuals with APS. Treatment of microvascular and catastrophic APS remains challenging. While the addition of various immunosuppressive agents is often utilized, further systemic evaluations of their use are warranted before definitive recommendations can be made. Several new therapeutic strategies are on the horizon that might enable more personalized and targeted APS management in the near future. SUMMARY: Although the knowledge of APS pathogenesis has grown in recent years, the management principles and strategies are largely unchanged. There is an unmet need for evaluating pharmacological agents, beyond anticoagulants, that target diverse thromboinflammatory pathways.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types.
Warum dies für die Hirudotherapie relevant ist
Dieses Review diskutiert internationale gesellschaftliche Behandlungsleitlinien für das Antiphospholipid-Syndrom (APS) und schlägt praktische Managementalgorithmen für verschiedene APS-Subtypen vor, einschließlich Thromboseprophylaxe, Schwangerschaftsmanagement und katastrophalem APS. Vitamin-K-Antagonisten und Heparin/NMH bleiben bevorzugte Behandlungen für die sekundäre Thromboseprophylaxe, wobei einige Leitlinien direkte orale Antikoagulanzien in ausgewählten Fällen unterstützen; das Review hebt außerdem ungedeckte Bedürfnisse für Therapien hervor, die über Antikoagulanzien hinaus auf thromboinflammatorische Signalwege abzielen. Das Abstract erwähnt weder Blutegel, Hirudotherapie, Hirudin noch irgendeine Blutegel-basierte Therapie. Die Relevanz für die ASH ist nicht gegeben, da das Review sich vollständig auf konventionelle und neu entstehende pharmakologische Ansätze für APS konzentriert, ohne jedwede Blutegel-bezogene Intervention zu adressieren.
Zitation
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Ambati et al. · Current opinion in rheumatology, 2023
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026